A trial involving more than 13,000 people with type 2 diabetes found that Mounjaro, or tirzepatide, was about as effective as its older drug Trulicity, or dulaglutide, in protecting heart health, according to a summary released by Eli Lilly and Co. The study found that tirzepatide led to a 16% lower rate of all-cause mortality, better kidney function and blood glucose control, and greater weight loss after three years.
Full Story: BioPharma Dive (7/31)